Lite Strategy operates a cryptocurrency treasury strategy alongside a legacy pre-clinical biopharmaceutical pipeline. The company's primary operational focus is holding Litecoin as its main reserve asset and writing covered call options against these holdings to generate income from option premiums. In parallel, Lite Strategy maintains a drug pipeline consisting of two candidates: voruciclib, which the company evaluates in pre-clinical studies for non-oncology indications, and zandelisib, which it evaluates for potential out-licensing or sale. The company has halted all clinical trials and does not sell commercial pharmaceutical products. Instead, Lite Strategy seeks to monetize its drug assets through licensing fees, milestone payments, or divestitures. Lite Strategy operates with a minimal internal workforce and relies on third-party contract research organizations, contract manufacturers, and external advisors to manage pre-clinical testing and treasury activities.